Besides, the expressions of Cpt1a, Acadm, Hadhb and Eci2 were up-regulated after SCO administration (Figure 6B), suggesting that SCO inhibit the progression of NAFLD may be closely related to regulating the process of fatty acid (triglyceride) synthesis and degradation. The gene discussed is HADHB; the disease is metabolic dysfunction-associated steatotic liver disease.